Kuan W-L, Barker R A
Cambridge Centre for Brain Repair, Cambridge University, UK.
Neurorehabil Neural Repair. 2005 Sep;19(3):155-81. doi: 10.1177/1545968305277219.
Parkinson's disease (PD) is a common neurodegenerative disorder of the brain and typically presents with a disorder of movement. The core pathological event underlying the condition is the loss of the dopaminergic nigrostriatal pathway with the formation of alpha-synuclein positive Lewy bodies. As a result, drugs that target the degenerating dopaminergic network within the brain work well at least in the early stages of the disease. Unfortunately, with time these therapies fail and produce their own unique side-effect profile, and this, coupled with the more diffuse pathological and clinical findings in advancing disease, has led to a search for more effective therapies. In this review, the authors will briefly discuss the emerging new drug therapies in PD before concentrating on a more detailed discussion on the state of cell therapies to cure PD.
帕金森病(PD)是一种常见的脑部神经退行性疾病,通常表现为运动障碍。该病症的核心病理事件是多巴胺能黑质纹状体通路的丧失以及α-突触核蛋白阳性路易小体的形成。因此,针对脑内退化的多巴胺能网络的药物至少在疾病的早期阶段效果良好。不幸的是,随着时间的推移,这些疗法会失效并产生其独特的副作用,再加上疾病进展中更广泛的病理和临床发现,促使人们寻求更有效的疗法。在这篇综述中,作者将简要讨论帕金森病中新兴的新药疗法,然后集中更详细地讨论治疗帕金森病的细胞疗法的现状。